We have the Brazilian licensure process ongoing, and we are targeting additional markets with established travelers markets, but also additional LMIC territories, including on the basis of WHO pre-qualification.
Aug 13, 2024 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2024-08-13 | transcript 92752cd0-9a10-4822-93fe-d645ec35ec4b | chars 8611-8822 | segment 8
So, many questions hopefully are able to capture those. So, I think on iXCHIC, We are really seeing, as you rightly pointed out, that we are having customers reordering ixchic, which is good because it means that slowly, slowly the vaccine is being taken up. I think it's a bit too early to really talk about this in detail. I think we have We have continued to grow the awareness of Chicken Gunja and XChick amongst HCPs. We also started to engage with customers. We have now sold doses across each of our sales channels, including a growing number of reorders, as I mentioned earlier. The number of customer accounts we are engaging with is growing as well. Additionally, we continue to see travelers proactively asking about CHIC, which is a fantastic achievement already right now. And access and coverage of XCHIC continues to improve. We had approximately 25% coverage last quarter, and now it's over 50%. And I think this is really an important step forward And as I said, there are a couple of things still outstanding, and there are some gating factors worth noting, including the fact that the ACRP recommendations for chikungunya have still not been published in the MMWR, which is important for driving broader reimbursement and prescribing of the vaccine by HDPs. So that's a little bit where we are on the ICSHIC front.
Aug 13, 2024 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2024-08-13 | transcript 92752cd0-9a10-4822-93fe-d645ec35ec4b | chars 29703-31036 | segment 29
Here we see clearly XJIC and the possibility to unlock the XJIC value by building awareness and market, capitalizing on the bundling effect with existing travel business and expanding globally, reaching more LMIC territories via strategic partnerships.
Aug 13, 2024 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2024-08-13 | transcript 92752cd0-9a10-4822-93fe-d645ec35ec4b | chars 4255-4507 | segment 4
And it's a wonderful plug and play because we are seeing here a very similar commercial footprint, namely travelers and military from high income countries, but LMICs as well, and here specifically children living in endemic countries.
Aug 13, 2024 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2024-08-13 | transcript 92752cd0-9a10-4822-93fe-d645ec35ec4b | chars 13063-13298 | segment 12
We activate consumers to seek travel health consults, and we ensure military officials understand the risk, impact, and threat levels associated with chikungunya.
May 7, 2024 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2024-05-07 | transcript c4d4b639-473c-4a9a-bf8b-6fd765eebe14 | chars 6024-6186 | segment 6
We hereby capitalize on the bundle effect within our existing travel business.
Mar 20, 2024 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2024-03-20 | transcript d9d99c70-eeb3-4bb3-ab00-b218bd637c55 | chars 4630-4708 | segment 4
And as previously described, BLA 1553, especially from a traveler's perspective, fits perfectly within our existing commercial infrastructure, but also in the industrial infrastructure.
Nov 9, 2023 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2023-11-09 | transcript 6d913e27-fb04-4634-b862-d9195397dce0 | chars 3346-3531 | segment 3
This includes, on the one hand side, maximizing the existing travel vaccines, leveraging continuous recovery of travel to pre-COVID levels and beyond from a volume perspective.
Nov 9, 2023 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2023-11-09 | transcript 6d913e27-fb04-4634-b862-d9195397dce0 | chars 14769-14945 | segment 15
Additional growth drivers, Of course, the continuous recovery of the travel market that will be reflected in substantial growth still in ICSIARO and Ducoral. As mentioned, the DoD contract for ICSIARO and then potential label expansion for VLA 15153 after the initial approval in adults. And then, of course, longer term in licensing or acquisition of additional clinical candidates and then potential market launch, of course, of these in licensed programs.
Sep 21, 2023 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2023-09-21 | transcript 9016c879-b696-4e87-8cfa-6ea940791d29 | chars 20507-20965 | segment 20
We have seen a significant rebound of the commercial business and we clearly capitalized on the strong recovery in the travel segment and we complemented our commercial portfolio with additional third-party product sales.
Mar 23, 2023 / CEO / receipt, needs a key / Thomas Lingelbach, CEO | earnings call 2023-03-23 | transcript 89aa2a9d-4fa2-4edd-8dda-f5caa3c3555f | chars 2311-2532 | segment 2